Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market From 2025 To 2029?
The market size of treatment for hereditary breast and ovarian cancer syndrome has seen significant growth in the past few years. The market is projected to increase from $6.72 billion in 2024 to $7.07 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. The expansion in the historic period has been driven by factors such as enhanced awareness and screening, supportive government initiatives, patient advocacy and agency, and collaborative research efforts.
In the near future, the hereditary breast and ovarian cancer syndrome treatment market is predicted to undergo substantial growth. The market size, currently projected to reach$8.98 billion in 2029, is expected to expand at a compound annual growth rate (CAGR) of 6.2%. Contributing factors to this predicted growth during the forecast period include the increasing importance of artificial intelligence, wider availability of genetic counseling, approval of targeted therapies by regulatory bodies, personalized treatment strategies, and international cooperation in research initiatives. Upcoming trends for this forecast period include developments in gene editing technologies, advancements in immunotherapy, technological progress in the field of oncology, the application of immunotherapy for BRCA-associated cancers, and a holistic approach to multidisciplinary care.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13209&type=smp
Which Factors and External Forces Are Driving Demand in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
The escalating occurrence of genetic conditions is anticipated to drive the expansion of the hereditary breast and ovarian cancer syndrome treatment market in the future. Newborn screening, which is a comprehensive physical assessment conducted shortly after birth to detect specific health conditions, enables healthcare professionals to identify and manage specific needs before they cause illness in a baby. This type of screening can help discover infants with a high propensity of developing breast and ovarian cancer, thereby enabling early commencement of preventive protocols. For instance, statistics from the Texas Department of State Health Services, an American state health organization, shows that in 2022 there was a 4.3% increase in the total specimens received for newborn screening, rising from 729,347 in 2021 to 761,000 in 2022. Moreover, approximately 394,000 babies were tested, and out of these, 1,130 babies were diagnosed with one of the NBS disorders in 2022. As such, the increasing prevalence of genetic disorders is spurring on the growth of the hereditary breast and ovarian cancer syndrome treatment market.
Which Segments in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Offer the Most Growth?
The hereditary breast and ovarian cancer syndrome treatmentmarket covered in this report is segmented –
1) By Treatment: Hormonal Therapy; Chemoprevention; Genetic Counselling; Medication; Other Treatments
2) By Diagnosis: Genetic Testing; Magnetic Resonance Imaging (MRI); Mammography; Other Diagnosis
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors
2) By Chemoprevention: Tamoxifen; Raloxifene
3) By Genetic Counselling: Risk Assessment; Family Planning Guidance
4) By Medication: Targeted Therapies; Immune Checkpoint Inhibitors
5) By Other Treatments: Preventive Surgery; Surveillance Strategies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13209&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?# Market?
North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Which Cutting-Edge Market Trends Are Expected to Drive theHereditary Breast and Ovarian Cancer Syndrome Treatment Market’s Growth?
Leading companies within the hereditary breast and ovarian cancer syndrome treatment industry are adopting innovative treatment plans such as comprehensive risk assessments in order to provide dependable services to their clientele. A comprehensive risk evaluation is a tool that assists in determining a person’s potential risk of developing or experiencing symptoms of a specific disorder or disease. For example, in February 2023, Genetic Technologies Limited, a molecular diagnostics company based in Australia, launched a ground-breaking risk evaluation tool that is designed to treat breast and ovarian cancer. This includes genetic mutation testing for these cancers, as well as assessments for both inherited and non-inherited risk factors, and the GeneType risk rating for both these cancers. Their unique method incorporates the detection of the 13 primary actionable genes associated with breast and ovarian cancer susceptibility with the GeneType testing platform. This new testing platform targets women over 30 who are at an above-average risk, due to uncommon genetic alterations, of developing breast and ovarian cancer compared to the general population.
View the full report here:
What Are the Key Elements That Define the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market?
The hereditary breast and ovarian cancer syndrome (HBO) treatment refers to the collective measures and medical approaches taken to address the elevated risk of developing breast and ovarian cancers in individuals with a genetic predisposition to the syndrome. Hereditary breast and ovarian cancer syndrome (HBO) treatment can help to prevent cancer from developing or detecting it early when it is more treatable.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13209
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model